• Inicio
  • Formações
  • Formação à Medida
  • News & Trends
  • Sobre nós
  • Contacto

Data Integrity and Compliance With Drug CGMP

FDA expects that all data be reliable and accurate (see the “Background” section). CGMP regulations and guidance allow for flexible and risk-based strategies to prevent and detect data integrity issues. Firms should implement  meaningful and effective strategies to manage their data integrity risks based on their process understanding and knowledge management of technologies and business models.

Data Integrity and Compliance With Drug CGMP .Questions and Answers Guidance for Industry

News & Trends

Procurar

Recentes

  • A Formiventos está novamente no ranking das Top 5% melhores PME de Portugal
  • Electronic Submission Template for Premarket Approval Applications (PMAs)
  • MDSAP Technical Review and Recognition Decision Procedure
  • Essential Principles and Content of Predetermined Change Control Plans. Final Document
  • Report on the International Active Pharmaceutical Ingredient Inspection Programme 2017 – 2024
  • GMP and GDP Question and Answer Guide Version 03 published by ECA
  • Guideline on good pharmacovigilance practices (GVP) Module III – Pharmacovigilance inspections (Rev 2)
  • Publication of COMBINE Project 2 Sponsors’ guide on safety reporting in combined studies

91 257 00 03 (Chamada para a rede móvel nacional)
info@formiventos.com

  • Follow
  • CLIENTES & TESTIMONIALS
  • ASSOCIAÇÕES OFICIAIS
  • CERTIFICAÇÕES E CREDITAÇÕES
  • ADVISORY BOARD
  • Política de Privacidade
  • Contacto